RxDoctor Payments DataLook up a doctor →

Michael Banov, MD

Psychiatry · Marietta, GANPI 1881771004

Payments from drug & device makers

$4,205,458in general payments, 2019–2025

Across 2,428 payments — averaging $1732.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$863K
  • Livanova USA, Inc.$597K
  • AbbVie$577K
  • Teva Pharmaceuticals USA, Inc.$531K
  • Sage Therapeutics, LLC$379K
  • Janssen Research & Development, LLC$277K
  • plus $982K from 45 others
$208,332in research payments, 2019–2025

Across 49 payments — averaging $4251.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Teva Pharmaceuticals USA, Inc.$144K
  • Arbor Pharmaceuticals, Inc.$44K
  • Sunovion Pharmaceuticals Inc.$19K
  • Supernus Pharmaceuticals, Inc.$1K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$687

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Otsuka Pharmaceutical Development & Commercialization, Inc.21$862,542
Livanova USA, Inc.210$596,709
AbbVie(2 entities)380$577,062
Teva Pharmaceuticals USA, Inc.188$531,109
Sage Therapeutics, LLC71$378,885
Janssen Research & Development, LLC43$276,926
Supernus Pharmaceuticals, Inc.113$140,367
Johnson & Johnson223$133,061
Axsome Therapeutics, Inc.152$120,842
E.r. Squibb & Sons, L.L.C.18$119,516
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)155$109,173
Sumitomo Pharma America, Inc.54$84,028
H. Lundbeck A S7$55,797
Sunovion Pharmaceuticals Inc.72$55,560
Neurocrine Biosciences, Inc.70$48,582
Alkermes, Inc.37$19,201
Vanda Pharmaceuticals Inc.47$17,663
Eisai Inc.77$16,262
Acadia Pharmaceuticals Inc11$15,052
Boehringer Ingelheim11$10,141
Almatica Pharma LLC34$8,627
Otsuka America Pharmaceutical, Inc.92$7,364
Takeda Pharmaceuticals U.S.A., Inc.58$6,798
Boehringer Ingelheim International GmbH4$4,060
Idorsia Pharmaceuticals US Inc15$3,133
Janssen Scientific Affairs, LLC1$2,525
Lundbeck LLC51$934
Neos Therapeutics, LP55$600
Avanir Pharmaceuticals, Inc.30$479
Corium, LLC23$411
Bausch Health US, LLC16$324
Noven Therapeutics, LLC17$275
Tris Pharma Inc12$245
Merck14$244
Ironshore Pharmaceuticals Inc.11$239
Jazz Pharmaceuticals Inc.6$116
Sanofi-aventis U.S. LLC1$102
Indivior Inc.3$75
Orexo US, Inc.4$73
Arbor Pharmaceuticals, Inc.4$63
Harmony Biosciences LLC3$45
Shire North American Group Inc3$43
Adlon Therapeutics L.p.2$36
Novartis1$31
Alfasigma USA, Inc.1$25
Collegium Pharmaceutical, Inc.1$22
Brainsway USA Inc1$21
Vertical Pharmaceuticals, LLC1$20
Masimo Corporation1$19
Neuronetics, Inc.1$16
Aytu Biopharma, Inc.2$14

How this compares

$4,205,458 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia →

Medicare billing

Part B allowed, 2024
$444,777
Medicare patients
204
Services billed
1,744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other psychiatry in Marietta

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →